Champignon brands expands alternative medicine IP portfolio with ketamine, adaptogenic delivery systems/formulations

Shares :

0
(0)

VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a health and wellness company specializing in the formulation of a suite of medicinal mushrooms and mushroom-infused products, today introduces new proprietary intellectual property (“IP”) into its vertically integrated alternative medicine product range. The Company is pleased to announce its entry into a definitive agreement, signed March 18, 2020, to acquire Novo Formulations Ltd. (“Novoformulations”).

Novoformulations’ novel delivery system platforms, as well as complementary R&D advancements, will accelerate the architecture of Champignon’s patent portfolio as the Company persists in being a first mover in the existing consumer package goods (“CPGs”) and emerging psychedelic medicine arenas.

Novoformulations is a specialty biotechnology company focused on developing novel and innovative delivery systems for the pharmaceutical and nutraceutical industries. The Novoformulations team consists of a roster of PhDs and technician level scientists, each with decades of experience building novel defensible medical IP, as well as subsequently developing and commercially marketing proprietary delivery platforms.

Novoformulations is presently working with ketamine, anaesthetics and adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built GMP and pharmaceutical (DIN) licensed facility (the “GMP Formulation Facility”) located in Quebec, Canada, and an accredited pharmacy in Ontario. There, the Company is actively formulating, developing and commercializing bioavailable delivery platforms, including:

  • Transdermal (topical);
  • Intranasal;
  • Sublingual; and,
  • Novel oral and suppository.

Also based in Quebec, Novoformulations’ manufacturing partner will process its novel delivery platforms and formulations into marketable end products at its 40,000-square-foot GMP-certified, Health Canada and Federal Drug Administration (FDA)-approved manufacturing facility.

Champignon plans to leverage Novoformulations’ existing product development infrastructure and licensed affiliates to pursue psilocybin and MDMA based formulations, with the objective of developing and commercializing rapid onset treatments capable of improving health outcomes, including Depression, PTSD and substance and alcohol use disorders (DPS). The current marketplace for pharmacologic DPS treatments in North America exceeds $10 billion annually.1

“The recent acquisitions of Novoformulations and Artisan Growers are absolutely accretive to each other and to our stated business objectives of enhancing the health and wellbeing of millions of consumers via our suite of medicinal mushroom extracts, mushroom-infused products and now novel delivery systems,”

  • Champignon Chief Executive Officer Gareth Birdsall commented.

 “The existing infrastructure inherited from these recent acquisitions positions us as a leading participant throughout the entire alternative medicine lifecycle, from R&D to formulation, manufacturing and end distribution. The end result will be a turnkey solution that incorporates both standardized ingredient mixtures and pharmaceutical grade products that can now be marketed via a variety of proprietary delivery systems,” continued Gareth Birdsall. “The addition of Novoformulations allows Champignon to deliver medications in a safer, more effective and more expeditious manner than our peers, from bench top in the laboratory, to preclinical and clinical trials. We are intent on the commercialization of products throughout North America, as rapidly as is safely and effectively practicable.”

The Novoformulations’ team works alongside multiple first-class university institutions, as well as collaborates with medical professionals and associated clinics in numerous Health and Wellness spaces that include: Psychiatry (depression, anxiety, PTSD, OCD); Addiction (alcohol drug, obesity); Neurology (concussion and neuropathic pain); Rheumatology (osteoarthritis, rheumatoid arthritis); Aging (dementia, probable Alzheimer’s, mini-strokes); and metabolic disorders (diabetes).

Champignon will also look to integrate its existing medicinal mushroom extracts, as well as fungi cultivated at its Artisan Growers’ facility, into certain proprietary delivery systems developed by Novoformulations. The Company has successfully formulated a functional mushroom blend, which includes but is not limited to the following fungi varietals:

  1. Reishi: an adaptogen with anti-inflammatory, cholesterol-lowering and known anti-viral properties;
  2. Lion’s Mane: a mushroom with adaptogenic-like properties for improved cognitive functions; and,
  3. Chaga: a mushroom with adaptogenic-like properties, which may act as a neuroprotective agent and may boast anti-viral and anti-cancer properties.

Under the terms of the Agreement, Champignon will acquire 100 percent of the issued and outstanding shares of Novoformulations for total consideration of 12.5 million common shares in the capital of the Company at a deemed price of $0.2475 per share. A finder’s fee is applicable to this transaction.

About Champignon Brands Inc. 

Champignon Brands Inc. (CSE: SHRM) is a Canada-based company dedicated to the distribution of artisanal medicinal mushrooms infused products. The Champignon team is mandated with enhancing the health and wellness of millions of potential consumers through the distribution of a premium, mushroom-infused product suite. Champignon continues to be inspired by sustainability, as all of its eligible SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.ChampignonBrands.com


Other company in the psychedelic market
This image has an empty alt attribute; its file name is revivelogo2.2.png

Other companies enter into psychedelic market with much more potential for investors like Revive Therapeutic | RVV with a market value of only $4 Million.

Revive Therapeutic | RVV just entered into LOI to acquire Psilocin Pharma Corp who has novel methods of production of Psilocybin-based formulations with six unique formulations for both natural and synthetically derived Psilocybin.

RVV has a market value of only $4 Million.

Revive Therapeutic | RVV targets Mental Health (450mm population), eating Disorders (70mm population) and addiction (240mm population)

In addition, Revive Therapeutic has 4 Exclusive licenses to patents in delivery system and liver disease and 2 FDA orphan drug designation for CBD in treatment of AIH and prevention IRI from solid organ transplantation. A market of more than $180 billion.

View the profile of Revive Therapeutic | HERE


LAST ALERT MADE MORE THAN 170% TO DATE. DONT MISS THE NEXT !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies.

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Disclosure : Revive Therapeutics Ltd is a paid clients of The Cannabis Stock.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :